Patents Assigned to AROCELL AB
  • Patent number: 11959919
    Abstract: Method of selecting treatment for a subject diagnosed with cancer comprises contacting antibody that binds specifically to thymidine kinase 1 (TK1) protein with a first body fluid sample before completing cancer treatment; determining a first amount of antibody binding to TK1 protein in the first sample; correlating the first amount to a first concentration of TK1 protein using a standard curve correlating an amount of antibody binding to recombinant human TK1 (rhTK1) and a concentration of rhTK1; contacting the antibody with a second body fluid sample within one to six months after the cancer treatment; determining a second amount of antibody binding to TK1 protein in the second sample; correlating the second amount to a second concentration using the curve; identifying the patient as having a high risk of future cancer relapse if the second concentration is ? the first concentration; and selecting an adjuvant treatment based on the identification.
    Type: Grant
    Filed: December 30, 2019
    Date of Patent: April 16, 2024
    Assignee: AROCELL AB
    Inventors: Sven Skog, Staffan Eriksson, Bernard Tribukait, Qimin He
  • Patent number: 10551385
    Abstract: Method of determining a likelihood of cancer relapse in a subject who has completed cancer tumor surgery, radiotherapy treatment and/or chemotherapy treatment comprises contacting an antibody that binds specifically to a serum form of thymidine kinase 1 (STK1) protein with a blood serum sample one to six months after completing the surgery and/or treatment, and before any cancer relapse has been detected; determining an amount of antibody binding to STK1 protein in the sample; correlating the amount of antibody binding to STK1 protein to a concentration of STK1 protein in the sample; and based on the concentration of STK1 protein in the sample, generating decision support information representative of a likelihood of cancer relapse in the subject one to ten years after completion of the surgery and/or treatment, the decision support information comprising a likelihood value defining one of a high or low likelihood of cancer relapse.
    Type: Grant
    Filed: November 21, 2016
    Date of Patent: February 4, 2020
    Assignee: AROCELL AB
    Inventors: Sven Skog, Staffan Eriksson, Bernard Tribukait, Qimin He
  • Patent number: 10100128
    Abstract: Monoclonal antibodies and fragments thereof are capable of binding to a serum form of human TK1. Kits and methods involve the use of such monoclonal antibodies or fragments.
    Type: Grant
    Filed: December 18, 2014
    Date of Patent: October 16, 2018
    Assignee: AROCELL AB
    Inventor: Staffan Eriksson
  • Publication number: 20160311927
    Abstract: The embodiments relate to monoclonal antibodies or fragments capable of binding to a serum form of human TK1 and to kits and methods involving the use of such monoclonal antibodies or fragments.
    Type: Application
    Filed: December 18, 2014
    Publication date: October 27, 2016
    Applicant: AROCELL AB
    Inventor: Staffan Eriksson
  • Publication number: 20100311081
    Abstract: A method of predicting the likelihood of cancer relapse in a patient undergoing treatment for cancer is provided. The binding response level of an immunoreactive material (IM) comprising thymidine kinase 1 (TK1) protein is determined in a body fluid sample of a patient and the likelihood of relapse of the cancer disease is predicted based on this determined IM binding response level. Those patients that run a risk of cancer progress and relapse 1-15 years after the cancer treatment may be identified directly by the IM binding response level within a few months following initiation of the treatment.
    Type: Application
    Filed: November 27, 2009
    Publication date: December 9, 2010
    Applicant: AROCELL AB
    Inventors: Sven SKOG, Staffan ERIKSSON, Bernhard TRIBUKAIT, Qimin HE